Home Newsfeeds Barclays Maintains Overweight on Gossamer Bio, Raises Price Target to $18

Barclays Maintains Overweight on Gossamer Bio, Raises Price Target to $18

Barclays analyst Carter Gould maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and raises the price target from $12 to $18.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Barclays analyst Carter Gould maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and raises the price target from $12 to $18.

News
Tech

Pinch And Play: Video Shows Off Humane AI Pin Using Palm As A Display Surface, Looks Futuristic Yet Tedious

By Rounak Jain

November 22, 5:39 AM

The futuristic-looking Humane AI Pin has appeared in action on video for the first time, revealing a cool but tedious looking user interface.

MSFT

Does Social Media Algorithm Impact Political Beliefs? Research Finds Limited Impact

By Anusuya Lahiri

July 28, 9:55 AM

Four new studies complicate the narrative around abolishing algorithms on Meta Platforms, Inc (NASDAQ: META) Facebook, and Instagram to prevent misinformation and political division.

Datasea Inc. And iPower Inc. Collaborate To Expand Product Distribution In U.S. Online Markets

By Benzinga Newsdesk

April 22, 10:03 AM

Datasea Inc. (NASDAQ:DTSS) ("Datasea" or the "Company"), a trailblazing digital technology company incorporated in Nevada, dedicated to innovative solutions in acoustic high tech and 5G-Artificial Intelligence ("AI")

DTSS